comparemela.com

Latest Breaking News On - Covaxin maker bharat biotech - Page 2 : comparemela.com

Coronavirus: India reports 44,111 new infections in last 24 hours, active cases under 5 lakh

Coronavirus: India reports 44,111 new infections in last 24 hours, active cases under 5 lakh Only eight states showed an increase in the number of active cases in the last 24 hours. Representative image: Motorists ride past a mural dedicated to frontline workers fighting against coronavirus. | Arun Sankar/AFP India on Friday morning reported 44,111 new coronavirus cases in the last 24 hours, taking its tally since the pandemic broke out in January 2020 to 3,05,02,362, data from the health ministry showed. The single-day rise is 5.37% lower than Friday’s count of 46,617 infections. The toll rose by 738 to 4,01,050, while the number of active cases dipped under five lakh to 4,95,533. Only eight states showed an increase in the number of active cases.

Coronavirus: Bharat Biotech confirms 77 8% efficacy of Covaxin in third phase trial data

Coronavirus: Bharat Biotech confirms 77.8% efficacy of Covaxin in third phase trial data The pre-print data of third phase trials of the vaccine shows 65.2% efficacy against the Delta variant. A health worker holding a vial of Covaxin at a vaccination centre in Delhi. | Adnan Abidi/Reuters Covaxin-maker Bharat Biotech early on Saturday confirmed that the coronavirus vaccine shows 77.8% efficacy against the infection. The company published the pre-print data of the third phase of the vaccine trials in the medical journal medRxiv. On June 23, reports citing unidentified officials had suggested that a Subject Expert Committee of the Central Drugs Standard Control Organisation had accepted trial data of the vaccine. This came after Bharat Biotech submitted the data to the Drug Controller General of India.

India s vaccine production in Aug-Dec likely to fall short of target: Report

India s vaccine production in Aug-Dec likely to fall short of target: Report India s vaccine production in Aug-Dec likely to fall short of target: Report According to a Reuters report, India s vaccine output for August-December this year may fall short of the govt s target of 1.46 billion doses. advertisement India has fully immunised only about 3% of its 1.35 billion people. (PTI) India s output of COVID-19 shots for August-December is likely to be lower than the government s public estimate, according to internal projections shared with Reuters by two sources. Lower-than-expected production could delay India s plans to vaccinate all its adults this year, amid fears the country will face another surge of coronavirus infections in the winter. India s ongoing second wave, the world s worst since the pandemic began, has overwhelmed its health system.

India s output of Covid shots for August-December is likely to be lower than govt s public estimate

India’s output of Covid-19 shots for August-December is likely to be lower than the government’s public estimate, according to internal projections shared with Reuters by two sources. Lower-than-expected production could delay India’s plans to vaccinate all its adults this year, amid fears the country will face another surge of coronavirus infections in the winter. India’s ongoing second wave, the world’s worst since the pandemic began, has overwhelmed its health system. The government last week publicly estimated 1.46 billion doses of its three approved shots AstraZeneca, Sputnik V and Covaxin would be made between August and December.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.